Figure 5

Figure 5

No changes in efferocytosis or cell corpse numbers were observed with neratinib treatment in chronic models of lung disease. Two different dosing protocols were used for neratinib treatment in the chronic lung disease model: induction dosing (A) and therapeutic dosing (B). Uptake of cell debris by macrophages was unchanged between treatment groups in both the induction dosing (C, D) and therapeutic dosing (E, F) models. The percentage of TO-PRO-3+ cells in BAL, assessed by flow cytometry, was unchanged in the induction dosing model (G) and the therapeutic dosing model (H). Leukocyte number in BAL and the percentage of neutrophils, macrophages, and lymphocytes were similarly unchanged across both models (I–P). Each data point in graphs represents data from one mouse; bars show mean ± standard deviation. Induction dosing study: n = 6 vehicle-treated mice, n = 7 neratinib-treated mice; therapeutic dosing study: n = 7 mice in each treatment group. Unpaired t-tests were used for statistical analysis.